Samsung Bioepis sues Janssen Biotech to invalidate Stelara patents
Intellectual Property 2024-02-08 11:48 pm By Christine Caulfield
Please login to bookmark Close

South Korean biosimilars company Samsung Bioepis has sued Johnson & Johnson’s Janssen Biotech to invalidate two patents for Crohn’s disease drug Stelara, after reaching a licencing agreement over the medicine in the US.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au